Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMUCH0)

• Drug Name: SHR2554 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1/2	[1]
Haematopoietic/lymphoid cancer	2B33.5	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMMUCH0

Molecule-Related Drug Atlas

Drug(s) Targeting Enhancer of zeste homolog 2 (EZH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazemetostat	DMWP1BH	Follicular lymphoma	2A80	Approved	[4]
DS-3201b	DMI69E5	T-cell leukaemia	2A90	Phase 2	[5]
CPI-1205	DM3XWJ8	Prostate cancer	2C82.0	Phase 1/2	[6]
CPI-0209	DMJEXLI	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
DS-3201	DMRLPFG	Acute lymphoblastic leukaemia	2A85	Phase 1	[6]
HH2853	DMQIE58	Non-hodgkin lymphoma	2B33.5	Phase 1	[8]
GSK2816126	DMJDVW4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
PF-06821497	DML3WT6	Diffuse large B-cell lymphoma	2A81	Phase 1	[10]
PMID28394193-Compound-56	DMQRFZK	N. A.	N. A.	Patented	[11]
PMID28394193-Compound-46	DMYMPNA	N. A.	N. A.	Patented	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Enhancer of zeste homolog 2 (EZH2)	TT9MZCQ	EZH2_HUMAN	Inhibitor	[3]

References

• [1] ClinicalTrials.gov (NCT03741712) A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03603951) A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms. U.S. National Institutes of Health.
• [3] Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [5] Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [9] National Cancer Institute Drug Dictionary (drug id 756211).
• [10] Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665.
• [11] EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.